Vericel Corp
Vericel develops, manufactures and markets cell therapy and specialty biologic products for sports medicine and severe burn care. Its U.S. portfolio includes MACI, an autologous cell therapy for repairing knee cartilage defects; Epicel, a skin replacement made from a patient’s own cells for certain severe burns; and NexoBrid, a licensed biologic for removing burn eschar. Vericel also sells MACI biopsy kits and custom instruments used for arthroscopic delivery of the implant. Vericel makes and sells MACI and Epicel in the U.S. and holds exclusive North American rights to commercialize NexoBrid. It sells MACI through specialty pharmacies, directly to hospitals and through a distributor; Epicel is sold directly to hospitals and burn centers, while NexoBrid is sold to specialty distributors for resale to hospitals and burn centers. Vericel is headquartered in Burlington, Massachusetts.
No SEC Form 4 filings for $VCEL in the last 30 days.
See all $VCEL insider activity →Vericel reported Q3 2026 revenue of $85.4M, up 26% YoY, with net income of $14.2M. Adjusted EBITDA was $25.2M, or 30% of revenue. The company raised full-year revenue guidance to $344M-$346M. MACI and Burn Care revenue grew 21% and 52%, respectively. Vericel repurchased 220,744 shares for $8.8M.
Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% t
MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning VCEL (Vericel Corp). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent VCEL coverage spans earnings, financial news and insider activity.
Guidance raise suggests stronger demand for MACI and Burn Care products, likely supporting the stock.
Positive earnings beat and raised guidance suggest upside potential.
VCEL benefits from the partnership and may see incremental upside from the expanded program.
Guidance raise and first buyback authorization are near-term catalysts, with margin guidance unchanged but EBITDA expansion expected to accelerate in 2027.
Raised guidance plus a new $200M buyback signals improving cash generation and supports a bullish near-term re-rating, though execution risk remains in commercial franchises.
AlphAI scores every news story that mentions VCEL with an AI model for sentiment and relevance, and aggregates insider trades from Vericel Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vericel reported Q3 2026 revenue of $85.4M, up 26% YoY, with net income of $14.2M. Adjusted EBITDA was $25.2M, or 30% of revenue. The company raised full-year revenue guidance to $344M-$346M. MACI and Burn Care revenue grew 21% and 52%, respectively. Vericel repurchased 220,744 shares for $8.8M.
Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% t
MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.
Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program Total Revenue Increased 22% to $77.
Flynn Sean C. (Chief Legal Officer) sold 15,000 shares of Vericel Corp (VCEL) at $45.64 ($0.68M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
Flynn Sean C. (Chief Legal Officer) sold 15,000 shares of Vericel Corp (VCEL) at $40.21 ($0.60M total) on 2026-06-18 under a Rule 10b5-1 trading plan.
Hopper Jonathan Mark (Chief Medical Officer) sold 4,375 shares of Vericel Corp (VCEL) at $35.00 ($0.15M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
Vericel Corporation (VCEL) has amended its corporate bylaws to reflect its new global headquarters located at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The amendment was approved by the Board of Directors and became effective on May 18, 2026. This change ensures that the company's official corporate records align with its updated principal executive office address.
Vanguard Capital Management has disclosed a 5.11% beneficial ownership stake in Vericel (NASDAQ: VCEL), amounting to 2,603,128 shares of common stock. This is reported via a Schedule 13G SEC filing, indicating Vanguard holds these shares for investment purposes across various affiliated funds and client accounts. The filing specifies Vanguard's sole voting power over 372,372 shares and sole dispositive power over all 2,603,128 shares.
